ORBIMED ADVISORS LLC 13D and 13G filings for Theseus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-12-27 4:43 pm Unchanged |
2023-12-22 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 17,713,600 40.100% |
0 (Unchanged) |
Filing |
| 2023-11-24 4:28 pm Unchanged |
2023-11-22 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 17,713,600 40.100% |
0 (Unchanged) |
Filing |
| 2023-07-19 4:12 pm Purchase |
2023-07-17 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 17,713,600 40.700% |
479,932 (+2.78%) |
Filing |
| 2023-03-14 4:19 pm Purchase |
2023-03-09 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 17,233,668 39.600% |
395,000 (+2.35%) |
Filing |
| 2021-11-18 5:10 pm Unchanged |
2021-11-15 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 16,838,668 43.500% |
0 (Unchanged) |
Filing |
| 2021-10-19 5:23 pm Purchase |
2021-10-12 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 16,838,668 44.900% |
16,838,668 (New Position) |
Filing |